An update on non-uterine gynaecological effects on raloxifene

European Journal of Cancer

Volumn 38, Issue SUPPL. 6, 2002, Pages

  Goldstein, S R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTCHROMAN; CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; ENDOMETRIAL DISEASE; HEART DISEASE; HUMAN; HYSTERECTOMY; LEUKORRHEA; NONHUMAN; PELVIS FLOOR; PELVIS SURGERY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; URINE INCONTINENCE; UTERUS DISEASE; UTERUS PROLAPSE; UTERUS WEIGHT;

EID: 0036753602     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(02)00291-5     Document Type: Article

References (4)

1. Grady D., Brown J.S., Vittinghoff E., Applegate W., Varner E., Snyder T. Postmenopausal hormones and incontinence. the Heart and Estrogen/Progestin Replacement study Obstet Gynecol. 97:2001;116-120.
2. Al-Jamal J.H., Dubin N.H. The effect of raloxifene on the uterine weight response in immature mice exposed to 17β-estradiol, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane, and methoxychlor. Am J Obstet Gynecol. 182:2000;1099-1102.
3. Black U., Sato M., Rowley E.Ret al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:1994;63-69.
4. Goldstein S.R., Neven P., Zhour U., Taylor Y.U., Ciaccia A.V., Plouffe L. Jr. Raloxifene effects on frequency of surgery for pelvic floor relaxation. Obstet Gynecol. 98:2001;91-96.